Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Current treatment for multiple myeloma.

× No keyword cloud information.

13 in total

Review 1. Oral targeted therapy for cancer.

Authors: Christine Carrington
Journal: Aust Prescr Date: 2015-10-01

2. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.

Authors: Jiye Liu; Tianyu Song; Wenrong Zhou; Lijie Xing; Su Wang; Matthew Ho; Zhengang Peng; Yu-Tzu Tai; Teru Hideshima; Kenneth C Anderson; Yong Cang
Journal: Leukemia Date: 2018-07-19 Impact factor: 11.528

3. Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels.

Authors: Yuan Jian; Wen Gao; Chuanying Geng; Huixing Zhou; Yun Leng; Yanchen Li; Wenming Chen
Journal: Oncol Lett Date: 2017-06-30 Impact factor: 2.967

4. Montelukast enhances cytocidal effects of carfilzomib in multiple myeloma by inhibiting mTOR pathway.

Authors: Jia Tong; Qing Yu; Wenbin Xu; Wenjun Yu; Chao Wu; Yingli Wu; Hua Yan
Journal: Cancer Biol Ther Date: 2018-10-25 Impact factor: 4.742

5. Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase.

Authors: Shaobing Gao; Chenlu Geng; Tianyu Song; Xuanru Lin; Jiye Liu; Zhen Cai; Yong Cang
Journal: J Biol Chem Date: 2017-01-13 Impact factor: 5.157

Current treatment for multiple myeloma.

Review 1. Oral targeted therapy for cancer.

2. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.

3. Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels.

4. Montelukast enhances cytocidal effects of carfilzomib in multiple myeloma by inhibiting mTOR pathway.

5. Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase.

6. Gamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells.

7. The antibiotic chloramphenicol may be an effective new agent for inhibiting the growth of multiple myeloma.

Review 8. BCMA-targeted immunotherapy for multiple myeloma.

Review 9. Notch signaling deregulation in multiple myeloma: A rational molecular target.

10. Gambogenic Acid Exerts Antitumor Activity in Hypoxic Multiple Myeloma Cells by Regulation of miR-21.